Cargando…
A RAPID POINT-OF-CARE DIPSTICK ASSAY FOR DIFFERENTIATION OF SARS-COV-2 VARIANTS IN COVID-19 PATIENTS
INTRO: Delta and Omicron variants of SARS-CoV-2 are highly contagious, currently dominating the globe and recognized as variant of concern (VOC). The transmissibility efficiency of viruses, disease symptoms, and severity of COVID- 19 is highly heterogeneous. Therefore, testing at the community level...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier Ltd.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10186954/ http://dx.doi.org/10.1016/j.ijid.2023.04.057 |
_version_ | 1785042658746433536 |
---|---|
author | Paul, D. Verma, J. Das, B. |
author_facet | Paul, D. Verma, J. Das, B. |
author_sort | Paul, D. |
collection | PubMed |
description | INTRO: Delta and Omicron variants of SARS-CoV-2 are highly contagious, currently dominating the globe and recognized as variant of concern (VOC). The transmissibility efficiency of viruses, disease symptoms, and severity of COVID- 19 is highly heterogeneous. Therefore, testing at the community level is essential to identify the infected people at an early stage-carrying VOC to reduce the spread of virus and combat the pandemic. METHODS: In this study, we analysed thousands of genome sequences representing 30 different SARS-CoV-2 variants and identified Delta and Omicron variants specific nucleic acid signatures in the spike gene. Based on the variant specific nucleic acid sequences we synthesized different oligos and optimized a mPCR assay that can specifically differentiate the Delta and Omicron variants. We further translated our work into a dipstick assay (Tohoku Bio-array, Japan) by adding tag linker sequence to 5’ end of the forward primer and adding biotin in 3’ end of the oligos. FINDINGS: A total of 250 samples were subjected to WGS using MiSeq platform and these confirmed samples were processed for validation of our specific designed probes using PCR assay and the readout was found to be 100% specific to Delta, BA.1 & BA.2 of SARS-CoV-2 variants which were further confirmed by Sanger sequencing. The dipstick was used to screen these samples, and specific signals were observed. WGS and Sanger sequencing were used to validate our PCR and dipstick assay results, and the readout was found to be 100% specific. The results can be visualised by the naked eye and interpreted easily. CONCLUSION: This study developed a rapid point-of-care test of SARS-CoV-2 patients, which can differentiate Delta, BA.1 and BA.2 variants at the same time of confirmation of the infection in patient. The current nucleic-acid chromatography-based dipstick assay is highly specific and can work even in the case of low viral load as well. |
format | Online Article Text |
id | pubmed-10186954 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Published by Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-101869542023-05-16 A RAPID POINT-OF-CARE DIPSTICK ASSAY FOR DIFFERENTIATION OF SARS-COV-2 VARIANTS IN COVID-19 PATIENTS Paul, D. Verma, J. Das, B. Int J Infect Dis Oral Session 7: COVID-19Date: Sunday, Nov 20, 2022 Time: 8:00-9:00Venue: Conference Hall #3 (CH3) INTRO: Delta and Omicron variants of SARS-CoV-2 are highly contagious, currently dominating the globe and recognized as variant of concern (VOC). The transmissibility efficiency of viruses, disease symptoms, and severity of COVID- 19 is highly heterogeneous. Therefore, testing at the community level is essential to identify the infected people at an early stage-carrying VOC to reduce the spread of virus and combat the pandemic. METHODS: In this study, we analysed thousands of genome sequences representing 30 different SARS-CoV-2 variants and identified Delta and Omicron variants specific nucleic acid signatures in the spike gene. Based on the variant specific nucleic acid sequences we synthesized different oligos and optimized a mPCR assay that can specifically differentiate the Delta and Omicron variants. We further translated our work into a dipstick assay (Tohoku Bio-array, Japan) by adding tag linker sequence to 5’ end of the forward primer and adding biotin in 3’ end of the oligos. FINDINGS: A total of 250 samples were subjected to WGS using MiSeq platform and these confirmed samples were processed for validation of our specific designed probes using PCR assay and the readout was found to be 100% specific to Delta, BA.1 & BA.2 of SARS-CoV-2 variants which were further confirmed by Sanger sequencing. The dipstick was used to screen these samples, and specific signals were observed. WGS and Sanger sequencing were used to validate our PCR and dipstick assay results, and the readout was found to be 100% specific. The results can be visualised by the naked eye and interpreted easily. CONCLUSION: This study developed a rapid point-of-care test of SARS-CoV-2 patients, which can differentiate Delta, BA.1 and BA.2 variants at the same time of confirmation of the infection in patient. The current nucleic-acid chromatography-based dipstick assay is highly specific and can work even in the case of low viral load as well. Published by Elsevier Ltd. 2023-05 2023-05-16 /pmc/articles/PMC10186954/ http://dx.doi.org/10.1016/j.ijid.2023.04.057 Text en Copyright © 2023 Published by Elsevier Ltd. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Oral Session 7: COVID-19Date: Sunday, Nov 20, 2022 Time: 8:00-9:00Venue: Conference Hall #3 (CH3) Paul, D. Verma, J. Das, B. A RAPID POINT-OF-CARE DIPSTICK ASSAY FOR DIFFERENTIATION OF SARS-COV-2 VARIANTS IN COVID-19 PATIENTS |
title | A RAPID POINT-OF-CARE DIPSTICK ASSAY FOR DIFFERENTIATION OF SARS-COV-2 VARIANTS IN COVID-19 PATIENTS |
title_full | A RAPID POINT-OF-CARE DIPSTICK ASSAY FOR DIFFERENTIATION OF SARS-COV-2 VARIANTS IN COVID-19 PATIENTS |
title_fullStr | A RAPID POINT-OF-CARE DIPSTICK ASSAY FOR DIFFERENTIATION OF SARS-COV-2 VARIANTS IN COVID-19 PATIENTS |
title_full_unstemmed | A RAPID POINT-OF-CARE DIPSTICK ASSAY FOR DIFFERENTIATION OF SARS-COV-2 VARIANTS IN COVID-19 PATIENTS |
title_short | A RAPID POINT-OF-CARE DIPSTICK ASSAY FOR DIFFERENTIATION OF SARS-COV-2 VARIANTS IN COVID-19 PATIENTS |
title_sort | rapid point-of-care dipstick assay for differentiation of sars-cov-2 variants in covid-19 patients |
topic | Oral Session 7: COVID-19Date: Sunday, Nov 20, 2022 Time: 8:00-9:00Venue: Conference Hall #3 (CH3) |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10186954/ http://dx.doi.org/10.1016/j.ijid.2023.04.057 |
work_keys_str_mv | AT pauld arapidpointofcaredipstickassayfordifferentiationofsarscov2variantsincovid19patients AT vermaj arapidpointofcaredipstickassayfordifferentiationofsarscov2variantsincovid19patients AT dasb arapidpointofcaredipstickassayfordifferentiationofsarscov2variantsincovid19patients AT pauld rapidpointofcaredipstickassayfordifferentiationofsarscov2variantsincovid19patients AT vermaj rapidpointofcaredipstickassayfordifferentiationofsarscov2variantsincovid19patients AT dasb rapidpointofcaredipstickassayfordifferentiationofsarscov2variantsincovid19patients |